Humana price target lowered to $250 from $364 at Barclays

Barclays analyst Andrew Mok lowered the firm’s price target on Humana to $250 from $364 and keeps an Equal Weight rating on the shares as part of a Q3 earnings preview for the health care facilities and managed care group. Underlying hospital trends remain strong, but the impact of two hurricanes may temper further upside to numbers this year and take away from a positive 2025 outlook, the analyst tells investors in a research note. For Humana, the firm expects significant focus on the stars path forward for 2026 and 2027, including avenues for litigation and mitigation. Barclays is also focused on the earnings impact from higher investment spend and lower interest rates, both of which it believes should weigh on Humana’s 2026 earnings before considering the direct stars impact.